

1 Investigation into Reversed Phase Chromatography Peptide Separation Systems Part I: 2 Development of a Protocol for Column Characterisation

3

4 Jennifer K. Field ^a, Melvin R. Euerby ^{a,b}, Jesper Lau ^c, Henning Thøgersen ^c, Patrik Petersson ^{c*}

5

6 ^a *Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United*
7 *Kingdom G4 0RE*8 ^b *Shimadzu UK, Milton Keynes, Buckinghamshire, United Kingdom MK12 5RD*9 ^c *Novo Nordisk A/S, Måløv, Denmark DK-2760*10 ** Author for correspondence, +45307 92146, pps@novonordisk.com*

11

12 Abstract

13 A protocol was defined which utilised peptides as probes for the characterisation of reversed phase
14 chromatography peptide separation systems. These peptide probes successfully distinguished
15 between differing stationary phases through the probe's hydrophobic, electrostatic, hydrogen
16 bonding and aromatic interactions with the stationary phase, in addition, to more subtle interactions
17 such as the phase's ability to separate racemic or isomeric probes.

18 The dominating forces responsible for the chromatographic selectivity of peptides appear to be
19 hydrophobic as well as electrostatic and polar in nature. This highlights the need for other types of
20 stationary phase ligands with possibly mixed mode functionalities / electrostatic / polar interactions
21 for peptide separations rather than the hydrophobic ligands which dominate small molecule
22 separations. Selectivity differences are observed between phases, but it appears that it is the
23 accessibility differences between these phases which play a crucial role in peptide separations i.e.
24 accessibility to silanols, the hydrophobic acetonitrile / ligand layer or a thin adsorbed water layer on
25 the silica surface.

26

27 Keywords

28 *Peptides; Protocol; RPC; Characterisation; Column Selectivity; Stationary phase*

29

30 1 Introduction

31 The biopharmaceutical industry is an expanding global market with a substantially increased market
32 share over recent years [1-2]. Many pharmaceutical companies are now investing significant
33 resources into developing biomolecules, which is a complex as well as expensive process. Peptides
34 and proteins present a different analytical challenge compared to small molecules due to their size

35 and physico-chemical properties. They therefore require a different approach for method
36 development activities. There are various publications which are intended to predict peptide
37 retention times based primarily on hydrophobicity and sequence. The success of these predictions is
38 based on an understanding of the role of hydrophobicity based on amino acid side chain differences
39 as well as the secondary structure of the peptide [3-7]. However, there are currently no publications
40 available describing a peptide-based approach for the characterisation and identification of columns
41 with different or similar selectivity for peptide separations to assist in developing methods.

42 The development of purity methods that separate the active pharmaceutical ingredient from its
43 impurities and degradation products is quite challenging and the potential presence of isomeric
44 species via racemisation in particular can be difficult to determine. Due to their identical mass to
45 charge ratio, isomers cannot be determined directly by mass spectrometry. Thus, screening of
46 combinations of columns and mobile phases that provide large differences in selectivity is of critical
47 importance for the development of purity methods for peptide-based drug products.

48 Chromatographic methods for biomolecules are often designed based on past experience. This lack
49 of a systematic approach can prove time consuming and a poor use of valuable resources. This is
50 contrary to small molecule separations where there are various articles on the retention
51 mechanisms of small molecules using different stationary phases, therefore method development
52 approaches and stationary phase selection can be made based on rational choice from column
53 characterisation protocols [8-14].

54 Column characterisation is a process which uses well defined molecular probes, under controlled
55 chromatographic conditions, which allows for direct comparison between different stationary
56 phases, manufacturer and batches of columns. For small molecule work there are many reversed
57 phase chromatography (RPC) characterisation protocols which have resulted in several databases,
58 the largest being Snyder's Hydrophobic Subtraction Model in the PQRI database and the Tanaka and
59 extended protocols by Euerby *et al.* in the ACD database which are both freely available on the
60 internet [9-13]. Lesellier *et al.* alternatively use supercritical fluid chromatography (SFC) to
61 characterise reversed phase stationary phases based on linear solvation energy relationships (LSER)
62 [14]. The different protocols can provide information on the hydrophobicity, steric interactions,
63 hydrogen bonding capability and ion exchange capacity of a column. It is, however, unclear how
64 relevant column characterisations based on small molecules are for the selection of columns for
65 peptides and proteins. This was confirmed by Hodges's *et al.* who concluded that there was very
66 little correlation between the small molecule PQRI database and the retention of a range of
67 peptides. The peptides in the study contained a high proportion of glycine residues to prohibit any
68 "nearest neighbouring effects" in order to gain a greater fundamental understanding of interactions

69 between each amino acid and the stationary phase, and to minimise any higher order structure such
70 as alpha helix and beta sheets [15-16]. Our study extends on Hodge's initial work to investigate
71 more biologically active peptides which would have potential interferences from "nearest neighbour
72 effects".

73 This first paper in a series will describe the design of a peptide-based characterisation protocol
74 known as the Peptide RPC Column Characterisation Protocol which will investigate the factors
75 contributing to the selectivity of reversed phase separation systems and assist in the development of
76 rational method development strategies for the separation of peptides using mobile phases selected
77 to meet industry best practices. This currently includes stationary phases but will also eventually
78 include mobile phase composition. This will increase the understanding surrounding selectivity of
79 peptide separations with general mechanisms investigated but also more specifically looking at
80 separations involving degradation and isomeric species. The characterisation protocol can be
81 adapted to develop a column characterisation database similar to that available for small molecule
82 reversed phase chromatography. A database will facilitate the identification of backup columns for
83 existing methodologies and highlight complementary stationary phase combinations with large
84 selectivity differences for method development purposes.

85

86 **2 Experimental**

87 **2.1 Chemicals and Reagents**

88 All water and acetonitrile used were of LC-MS grade and supplied by Sigma Aldrich (Poole, UK). The
89 compounds used in the system suitability test (SST) and the mobile phase additives (ammonium
90 formate, formic acid and trifluoroacetic acid) were also supplied by Sigma Aldrich. Dimethylsulfoxide
91 (DMSO) was supplied by Fisher Scientific (Hemel Hempstead, UK). The peptides, which were
92 supplied by Apigenex (Prague, Czech Republic), were all dissolved individually in DMSO/H₂O (80:20
93 v/v) to a concentration of 0.25 mg/mL. Solutions were stored at -20 °C.

94

95 **2.2 Chromatographic Conditions**

96 LC separations were performed on a Shimadzu Nexera X2 UHPLC system (Duisberg, Germany)
97 equipped with two binary pumps (LC-30AD) and proportionating valves, degassers (DGU-20A_{SR}),
98 autosampler with cooling capabilities (SIL-30AC), Prominence column oven (CTO-20AC), diode array
99 detector (SPD-M30A) and communication bus module (CBM-20A). A Shimadzu single quadrupole
100 Mass Spectrometer (LCMS 2020) was used as a secondary detector with positive electrospray

101 ionisation. The LC configuration had a dwell volume of 342 μL and system retention volume of 14 μL
102 [17]. The software used to control the LC system was LabSolutions (Version 5.86).

103

104 **2.2.1 Peptide RPC Column Characterisation Protocol Conditions**

105 The test conditions utilised both low and intermediate pH to affect selectivity. The low pH mobile
106 phases were prepared as follows A1: 0.1% v/v formic acid in water and B1: 0.1% v/v formic acid in
107 acetonitrile. Formic acid was dispensed using a 1000 μL variable pipette where accuracy was
108 confirmed at each preparation of mobile phase. The gradient at low pH was as follows: 5-45 %B over
109 40 minutes, where it was held at 45%B for 2 minutes, before dropping to initial conditions in 0.1
110 minutes, and re-equilibrated for 12 minutes (equivalent to 10 column volumes). The intermediate
111 pH mobile phase was prepared as follows A2: 20 mM ammonium formate in water and B2: 20 mM
112 ammonium formate in acetonitrile/water (80:20 w/w). Solutions were prepared from a 200 mM
113 stock buffer solution (native pH 6.45). The gradient at intermediate pH was as follows: 5.6-61.9 %B
114 over 40 minutes, where it was held at 61.9%B for 2 minutes, before dropping back to initial
115 conditions in 0.1 minutes. The system re-equilibrated for 12 minutes (equivalent to 10 column
116 volumes). Initial investigations utilised a B solvent consisting of 90% acetonitrile, however, the
117 resulting solution was initially turbid with the 200 mM ammonium formate which would become
118 homogeneous upon sufficient mixing. However, in order to increase the ruggedness of the protocol,
119 the B solvent was changed to 80% acetonitrile and the %B/min change adjusted accordingly to the
120 percentages described in this paper to maintain selectivity.

121 Separations were performed at 40 $^{\circ}\text{C}$ and 0.3 mL/min flow rate. A wavelength of 215 nm was used
122 with background correction at 360 nm, with bandwidths of 8 and 100 nm, respectively. Selected ion
123 monitoring (SIM) in positive ESI mode was used to track the peaks based on the $z=2$ charge, which
124 was the most abundant ion for the majority of the peptides. Isomers were tracked based on m/z and
125 peak area using different concentration in the same sample.

126 The programmable autosampler was used to prepare the peptide mixtures within the autosampler,
127 allowing for minimal waste of sample. These test mixtures contained two reference peptides, which
128 covered the range in hydrophobicities (i.e. a weakly and strongly retained peptide). Each peptide
129 mixture contained between 5-7 peptides (see Table 3 for a list of the peptides). Samples were stored
130 in the autosampler at 10 $^{\circ}\text{C}$.

131 So as to investigate whether TFA masked certain interactions, the mobile phases were as follows A3:
132 0.1% v/v TFA in water and B3: 0.1% v/v TFA in MeCN. TFA was dispensed from 1 mL aliquots. The
133 same gradient was used as formic acid on the columns described in Section 2.3, whilst all other

134 operating parameters were as described above. The procedure was applied to a reduced number of
135 peptides which were found to be the most discriminating for column characterisation.

136

137 **2.2.2 System Suitability Test Conditions**

138 The SST mixture contained water or uracil (dead time marker), benzylamine (changes in silanophilic
139 activity and negative charge), benzene sulfonic acid (changes in positive charge), benzyl alcohol,
140 caffeine (changes in hydrogen bonding), phenol (changes in phenolic interactions [18]), toluene,
141 butyl benzene and pentyl benzene (changes in hydrophobicity). 0.1% formic acid v/v in water was
142 assigned to Line A1 and 0.1% formic acid v/v in acetonitrile was assigned to Line B1. A gradient of
143 5%B at 0 minutes increased to 100% over 20 minutes, where it was held for 2 minutes before
144 dropping to initial conditions in 0.1 minute. The column was re-equilibrated for 12 minutes.

145 Separations were performed at 40 °C and 0.3 mL/min flow rate. Wavelengths of 215 and 254 nm
146 were used with background correction at 360 nm, and bandwidths of 8 and 100 nm, respectively.

147

148 **2.3 Columns**

149 All columns assessed were new as supplied by the manufacturer and were standardised in the 150 x
150 2.1 mm column format, with particle size (d_p) varying between 1.7 to 3 μm (Table 1). The peak apex
151 of a water injection was used as the dead time marker for each column [17]. All stationary phases
152 were assessed using Tanaka and extended characterisation protocols which are well described in
153 literature [9,19] and can be accessed via the free ACD website [11]. The integrity of the stationary
154 phases was ensured before and after usage by an SST (Section 2.2.2) which assessed the column for
155 changes in hydrophobicity, hydrogen bonding, positive charge and negative charge (silanol activity).

156 The selection of the stationary phases was based on prior knowledge of the columns and it was
157 presumed would offer a wide range in selectivity to be representative of a larger collection of
158 stationary phases, ideal for a characterisation database. Some columns possessed a large positive
159 charged surface whilst others had a high degree of residual silanol groups in order to characterise a
160 wide array of column functionalities. Some of the columns chosen would not normally have been
161 selected when developing state of the art peptide methods but were essential to establish a
162 database.

163 An array of C18 phases were selected which differed by base silica (i.e. Acquity BEH C18, Acquity CSH
164 C18 and Acquity HSS C18). In addition to selecting columns which could offer different selectivity, it
165 is of interest to investigate the subtleties between similar phases to be able to identify back up

166 columns. The ligand density was also evaluated which could impact on selectivity by changing the
167 architecture of the particle and accessibility to the silica surface (i.e. Acquity HSS C18 SB and Acquity
168 HSS T3).

169 A series of alkyl lengths were also evaluated to assess the effect of varying hydrophobicity where
170 observed selectivity differences can possibly be explained as a function of chain length differences
171 (i.e. Acquity BEH C4, Acquity BEH C8 and Acquity BEH C18).

172 A commonly used range of columns include polar embedded group (PEG) and phenyl phases, which
173 can offer alternative selectivity. A carbamate ligand (Acquity BEH Shield RP18) and an amide ligand
174 (Polar Amide C18) were selected to represent two styles of PEG functionalities and synthetic routes,
175 where the amide phase is prepared via a two-step synthetic route which generates positive
176 character to the phase due to residual amino groups, whilst the carbamate is a one-step synthetic
177 route thus can be considered neutral. The phenyl phases (i.e. Acquity CSH Fluoro Phenyl, Acquity
178 CSH Phenyl Hexyl, Ascentis Express Biphenyl and Fortis Diphenyl) vary by alkyl linker (i.e. C3-C6),
179 fluoro-substitutions and the number of aromatic rings, which all impact on the available interactions
180 with probes.

181 The final phase selected to develop the characterisation protocol was the Acclaim Mixed Mode WCX,
182 which is a weak cation exchange phase based on a carboxylic acid moiety. This phase can offer
183 hydrogen bonding interactions at low pH with the protonated carboxylic acid moiety and substantial
184 electrostatic interactions at intermediate pH via the negatively charged dissociated carboxylic acid.
185 Both types of interactions might provide selectivity differences for polar and charged peptide
186 species.

187

188 **2.4 Software and Calculations**

189 Principal Component Analysis (PCA) was performed using SIMCA (Version 14.1, Umetrics, Umeå,
190 Sweden) and Origin (Version OriginPro 2016, OriginLab, Northampton, MA, USA). The variables
191 within the PCA were all autoscaled, in order to give each variable the same importance. The net
192 charges of the peptide probes were calculated at both pH 2.5 and 6.45 using General Protein/Mass
193 Analysis for Windows (GPMW) software (Version 9.51, Lighthouse Data, Odense, Denmark).

194

195 **3 Results and Discussion**

196 **3.1 Rationale for Design of Peptide**

207 Bovine GLP-2, which is similar to Human GLP-2, was selected as the base sequence to probe the
208 stationary phases (Table 2). It is relevant to the biopharma industry, has a typical chain length and
209 possesses typical degradation sites. Additionally, Bovine GLP-2 is an attractive probe as it does not
210 contain cysteine which is likely to limit the stability of peptides due to sulfide bridge formation or
211 shuffling [20].

212 The peptide chain contains 33 amino acids, and has the propensity to form secondary structures
213 such as alpha helix or beta sheets. The length of the peptides was reduced to 15 and 18 amino acids
214 to reduce the probability for a secondary structure in an aqueous environment [21]. This length is
215 similar to the length typically obtained by proteolytic digests of proteins [16]. A lack of secondary
216 structures was confirmed using circular dichroism in organic / aqueous conditions and temperature
217 corresponding to the chromatographic conditions where the characteristic absorbances were absent
218 for any higher order structure [22].

219 Bovine GLP-2 can be viewed as having a more hydrophilic segment (amino acids 1-15, in Table 2) and
220 a more hydrophobic segment (16-33). The use of the two base sequence segments instead of the
221 single peptide would minimise the probability of secondary structures and allow for a selection of
222 peptide probes to be synthesised which potentially could be explained in terms of retention and
223 selectivity. In total, 26 rationally designed peptide probes were synthesised to characterise the
224 peptide separation system. The altered position in the peptide sequence and physico-chemical
225 properties (i.e. logP, pI and net charge) can be seen in Table 3.

226 The peptide chain contained several sites for common degradation, which include racemisation,
227 isomerisation, oxidation and deamidation. Racemisation can occur at the chiral centre of the α
228 carbon forming the D-isomer, where the rate of racemisation can depend on reaction parameters
229 such as pH, temperature and solvents. This is particularly prevalent for serine and histidine which are
230 known to be susceptible to racemisation during the synthetic process [23-24]. The sequence
231 provided four racemisation sites for serine or histidine (Peptide Numbers 2, 6, 7 and 14). Aspartic
232 acid is also known to undergo racemisation in addition to isomerisation to the isoaspartate, thus a
233 further eleven analogues were synthesised to probe the separation of the racemic and isomeric
234 degradants (Peptide Numbers 3, 4, 5, 9, 10, 11, 12, 16, 17, 18 and 19).

235 Oxidation can be explored via the methionine residue at position 10 in the chain (Peptide Number
236 8). It can readily oxidise during the synthetic process or during storage into two diastereoisomeric
237 sulfoxide species by means of the lone pair of electrons on the sulfur in a 1:1 ratio.

228 The loss of an amide functionality from a peptide is known as deamidation. This is observed for the
229 amino acids glutamine and in particular asparagine [25-26], especially when adjacent to an amino
230 acid such as glycine, serine or threonine. A cyclic succinimide intermediate forms between the
231 peptide bond and the asparagine side chain, which can ring open to form both the D- and the L-
232 forms of aspartate or isoaspartate via hydrolysis. A series of deamidation, racemisation and
233 isomerisation were explored using Peptide Numbers 9-12.

234 The more hydrophobic peptide chain was typically used to investigate specific modifications at
235 certain points of the peptide chain, with the intention of gaining a greater understanding of the
236 peptide-column interactions by examining a series of modifications (Peptide Numbers 13,15,20-26).

237 Steric interactions are particularly subtle, but are still an important modification to investigate.
238 Racemisation can be seen as a form of steric interaction. Other steric interactions probed include
239 substituting leucine (Peptide Number 13) for valine and isoleucine (Peptide Number 20 and 21),
240 which differs by a methylene group and branching and by switching the order of two amino acids
241 (Peptide Number 15).

242 Changing the charge of the peptide can have a substantial effect on its retentivity and can be
243 affected by different stationary phase, mobile phase composition and pH. It is possible to investigate
244 the effect of a small change in polarity and basicity with the same charge by modifying arginine (side
245 chain pK_a 12.48, Peptide Number 13) in position 20 with a lysine (side chain pK_a 10.35, Peptide
246 Number 25). The effect of changing from a neutral amino acid to a positive species can also be
247 investigated with the addition of lysine in place of leucine in position 26 in Bovine GLP-2 (16-33)
248 (Peptide Number 26). An increase in negative charge was probed by the addition of an aspartic acid
249 in various positions along the chain (Peptide Numbers 4, 5, 9, 10, 11, 12, 16, 17, 18 and 19).

250 Other mechanisms of interest were aromatic and phenolic effects, which were investigated by
251 exchanging leucine for phenylalanine, tryptophan or tyrosine (Peptide Numbers 22, 23 and 24,
252 respectively). Small molecules are highly influenced by aromatic and phenolic effects, however, it is
253 uncertain how the change of a single amino acid in a peptide will impact on selectivity, since this is a
254 relatively subtle modification of the peptide compared to a small molecule. Mant *et al.* did observe
255 selectivity differences on a range of peptides similar in size which differed by one amino acid [16,27],
256 however, their peptides had several glycine residues throughout the sequence to prevent any
257 secondary structure. This might not be the case for biologically active peptides which typically are
258 more heterogenic.

259

260 3.2 Rationale for Selection of Buffers

261 Peptide analysis at low pH typically includes either of the following mobile phase additives:
262 phosphate salts, trifluoroacetic acid (TFA), ammonium formate, ammonium acetate or formic acid
263 [28-29]. Phosphate salts are frequently used within the biopharmaceutical industry for peptide
264 separations as they often provide a favourable selectivity and peak shape, however, they were not
265 favoured in the protocol due to their lack of volatility which prohibits peak identification using MS
266 detection. TFA is a frequently used additive as it is a good compromise, i.e. it gives both acceptable
267 chromatographic and MS performance. It was not selected for the protocol as it was shown to mask
268 electrostatic and more subtle polar interactions between the peptides and the stationary phases
269 hence reducing the discriminating power of the column characterisation protocol (see section 3.4).
270 As it can also irreparably modify the stationary phase surface, it would be impractical for the
271 protocol, in that once exposed to TFA the column could not be used with other additives in the
272 characterisation protocol [30]. The intention of this present study was to develop a simple and
273 robust column characterisation protocol, by differentiating the subtle interactions of peptides with
274 the stationary phase surface and not to develop optimum LC methods. TFA and other interesting or
275 commonly used mobile phases will however be characterised in a following study which could
276 potentially aid the chromatographer in the selection of the most appropriate mobile phases for
277 method development.

278 The primary rationale for selecting formic acid as the mobile phase additive for the column
279 characterisation protocol was its lack of masking subtle interactions (compared to TFA) and hence
280 enhance the discriminating power of the protocol. Additional benefits included its ease of tracking
281 peaks using MS detection, volatility and lack of signal suppression in positive electrospray ionisation.
282 Formic acid would not normally be used for LC-UV due to the poor peak shapes that it typically
283 generates but is advantageous in that it permits the user to understand the purer interactions of the
284 stationary phase.

285 Historically, peptide analysis was performed at low pH in order to minimise the interaction of
286 peptides with deprotonated residual silanols at intermediate pH which can cause detrimental band
287 spreading and excessive tailing for ionised species. However, intermediate pH should still be
288 considered due to the alternative selectivity which it confers by changing the physico-chemical
289 properties of both the stationary phase and peptides.

290 Intermediate pH can be established using ammonium formate at its native pH (6.45). Although there
291 is little buffering capacity at this pH it is LC-MS compatible. An alternative to the formate salt could
292 be ammonium acetate, however, there is various anecdotal evidence which suggested that the

293 acetate salt produced significant adducts in the MS and ion suppression. Both salts are known to be
294 hygroscopic, which can be problematic for consistent results. This often manifests as clumping in the
295 salt container but is frequently ignored despite its effect on buffer concentration. A sodium chloride
296 salt chamber was set up at 20 °C to produce a relative humidity (RH) of 75.47% ±0.14 [31]. Over 6
297 hours the ammonium acetate had increased in mass by 32.9% and reduced to a liquid, whereas the
298 ammonium formate had a mass increase of 24.8% and was partially crystalline. A less exacerbated
299 scenario was set up at ambient humidity using a magnesium chloride salt chamber (RH 33.07%
300 ±0.18), which saw a mass increase of 7.9% for ammonium acetate and 3.3% for ammonium formate
301 over 6 hours. A comparison of ammonium acetate and ammonium formate highlighted no
302 difference in the degree of cluster formation in the MS, although there was some improved
303 sensitivity achieved with the formate salt on a selection of peptides (up to 2x greater), thus
304 ammonium formate was used to characterise the stationary phases at intermediate pH.

305

306 3.3 Normalisation and Definition of Selectivity

307 Two reference peptides were included in each peptide mixture in order to monitor any retention
308 time drift and to normalise retention time. The normalisation can also minimise variation related to
309 instrumentation, solvents, analyst and remove any contribution from the dwell volume of the
310 system (V_d) and column volume (V_m) in order to gain greater robustness for the overall procedure
311 (Eq. 1). Normalisation of the peptide's retention was feasible due to the fact that the peptides were
312 focused on the top of the column [32-35].

$$313 \quad t_g^* = \frac{t_g - t_{g\ Ref1}}{t_{g\ Ref2} - t_{g\ Ref1}} \quad (1)$$

314 Where t_g is the retention in gradient elution, $t_{g\ Ref1}$ is the retention in gradient elution of the first
315 eluting isomer of [Met(O)10]-Bovine GLP-2 (1-15) (Peptide Number 8a) and $t_{g\ Ref2}$ is the retention in
316 gradient elution of [Ile26,Leu27]-Bovine GLP-2 (16-33) (Peptide Number 15) (Fig. 1). These peptides
317 are the first and typically last eluting compounds, thus t_g^* values generated were between 0 and 1.

318 Selectivity in gradient chromatography (α^*) has been defined in various publications [33-34] where
319 gradient chromatography presents a more complex situation than for isocratic chromatography in
320 that changing eluent composition, dwell volume, column dead volume and gradient shape can all
321 influence the selectivity. A variety of α^* measures were evaluated using the peptides with the most
322 robust and intuitive defined equation in Eq. 2, where t_g is the retention time in gradient elution and
323 t_m and t_d are column dead time and dwell time, respectively.

324
$$\alpha^* = \frac{t'_{g2}}{t'_{g1}} \quad (2)$$

325
$$t'_g = t_g - t_m - t_d \quad (3)$$

326 However, the result produced by α^* was heavily dependent on the point of elution in the gradient,
327 despite visually having a similar degree of separation. The peptides of interest would produce a
328 reduced α^* value if retained for longer on the gradient in comparison to a less retained pair of similar
329 separating power, thus suggesting selectivity differences. Therefore, an alternative measure was
330 required to define selectivity.

331 A better representation of selectivity was delta (Δt_g^* , Eq. 4), which was the difference in normalised
332 retention time between two peaks. Delta values were preferred over α^* , as it rectified the
333 discrepancy to provide identical selectivity, regardless of the point of elution in the gradient. This
334 measure allowed direct comparison between stationary phases and mobile phases irrespective of
335 the point of elution, thus giving a purer representation of the selectivity differences. In addition, Δt_g^*
336 also compensates for differences in dwell time (t_d).

337
$$\Delta t_g^* = t_{g2}^* - t_{g1}^* \quad (4)$$

338 In total, 33 delta values per mobile phase were identified based on various properties, including
339 racemisation, steric interactions, increases in positive charge or negative charge, changes due to
340 oxidation and change in hydrophobicity / alkyl and changes in hydrogen bonding or aromatic
341 character (Table 4). The average Δt_g (expressed in minutes) and average Δt_g^* were recorded in Table
342 4 for the formic acid, TFA and ammonium formate gradient conditions, to allow for better
343 judgement of what is a large or small difference in selectivity. The sign in front of the Δt_g^* result is
344 indicative of the elution order for the separation. The largest average difference was observed using
345 formic acid between [Leu26]- and [Lys26]-Bovine GLP-2 (Peptide Number 13 and 26, respectively),
346 which could be expected due to the changes in charge. The smallest average differences (i.e. Δt_g^*
347 values close to zero) were typically racemic in nature, which highlights the difficulty in separating
348 these closely related species. The difference in responses for the position of the racemisation also
349 accentuates the issue of analysing racemates, where [L-Ser5] \rightarrow [D-Ser5] and [L-Ser7] \rightarrow [D-Ser7]-
350 Bovine GLP-2 (1-15) differ at position 5 and 7 respectively in the residue chain, but produced some
351 significant differences in Δt_g^* for both formic acid and ammonium formate (Peptide Number 1, 6 and
352 7).

353

354 **3.4 Principal Component Analysis**

355 A significant amount of information was produced in the data matrix thus the chemometric tool
356 Principal Component Analysis (PCA) was used to visualise trends within the data, by reducing the
357 number of variables (i.e. delta values) to two principal components [9,36]. The delta values were all
358 coded based on the interaction of interest (Table 4). The loading plot (Fig. 2) illustrates how the
359 different delta values contribute to the two principal components. Delta values located close to each
360 other have similar importance for the differentiation of objects (i.e. columns). 56% of the variation
361 between columns were described using two principal components. The use of a third principal
362 component increased the variation described by only 11% and did not provide any additional
363 information, thus only two principal components were used. The corresponding score plot (Fig. 3)
364 shows how similar or different columns are to each other. Columns located close to each other are
365 more similar. The columns in Fig. 3 were all colour coded based on prior knowledge of stationary
366 phase properties to gain an understanding of potential groupings. The green circles are phases with
367 neutral character i.e. high hydrophobicity and low degree of silanophilic interactions due to greater
368 ligand density and end-capping. The blue squares are phases with negative character, such as those
369 with low ligand coverage or absence of end-capping and thus a high degree of silanophilic
370 interactions. The inverted red triangles are phases with positive character i.e. presence of a
371 positively charged group in addition to the hydrophobic ligand [11].

372 The Acclaim Mixed Mode WCX was excluded from the PCA despite adequate peak shape and
373 performance under low pH conditions for all the peptides, as the carboxylic acid moiety on the
374 mixed mode phase was ionised at pH 6.45, which resulted in poor retention of Peptides 1-12. These
375 peptides can be considered more hydrophilic and possess a charge between -3.7 and -4.7 at the
376 intermediate pH. The affected peptides eluted in the void under those chromatographic conditions,
377 which would heavily skew the score and loading plots, thus the decision was made to exclude the
378 Acclaim Mixed Mode WCX for the purpose of comparison. A biplot was created solely from formic
379 acid data on all 14 columns, where the Acclaim Mixed Mode WCX was grouped with the negative
380 character stationary phases and located as far from the origin as the Acquity CSH Fluoro Phenyl and
381 consequently should display very different selectivity for appropriate peptides i.e. peptides with
382 limited negative net charge.

383 The possibility of reducing the number of delta values required for the Peptide RPC Column
384 Characterisation protocol was evaluated by performing an iterative study which removed any
385 variable near the origin in the loading plot (i.e. considered an insignificant variable), or removal of
386 variables with similar meanings whilst ensuring the integrity of the score plot was maintained (i.e. a
387 maintained relative location of columns). Following a step-wise process of elimination, the number
388 of variables within the Peptide RPC Column Characterisation Protocol was reduced from 66 to 11,

389 whilst still covering an array of important interactions. Six of the measurements were determined in
390 ammonium formate, whilst the remaining five were measured in formic acid, using a total of three
391 test mixtures (summarised in Table 5). The delta value to be measured were calculated from the
392 same test mixture to increase the robustness of the procedure.

393 A biplot of the final Peptide RPC Column Characterisation Protocol peptides (i.e. a combined score
394 and loading plot, Fig. 4) highlighted the influence an observation has on the position of the
395 stationary phase. Regions of electrostatic interactions can be deciphered, where the phases with
396 negative character in the upper quadrants (e.g. Acquity HSS C18-SB and Acquity BEH C4) are
397 dominated by the positive charge delta values, and the phases with positive character in the lower
398 quadrants (e.g. Polaris Amide C18 and Acquity CSH Phenyl Hexyl) are correlated with the negative
399 charge delta values. There is also an intermediate region of low electrostatic interactions for the
400 stationary phases with a neutral character which have low silanophilic activity due to high ligand
401 density and extensive end-capping.

402 In order to investigate the hypothesis that TFA masks certain interactions between the column and
403 the peptide, a study was conducted where 0.1% v/v formic acid was substituted with 0.1% v/v TFA in
404 both the aqueous and organic phase on the reduced number of delta values. 13 columns were
405 tested using a simplified and more robust version of the protocol described in reference [37] which
406 used 8 of the 11 probes to increase the reliability of the methodology. Distinct groups can be
407 observed in the formic acid biplot plot Fig. 5(A) with 87% of the variability described, where the
408 position of the columns can be rationalised based on what is known about the column characters.
409 With TFA, it is no longer possible to see these distinct groupings, and only 68% of the variability is
410 described, which suggests a less clear structure for that dataset (Fig. 5(B)). This would appear to
411 confirm the hypothesis that TFA will mask peptide-column interactions and thus columns become
412 more similar. Stationary phases such as the Acquity HSS C18-SB with no end-capping and low surface
413 coverage appear similar to columns with end-capping and positive charge like Acquity CSH Fluoro
414 Phenyl and Polaris Amide C18 which are very different. As such, to describe the interactions of the
415 columns, it is important to assess each column using formic acid, rather than TFA. A further
416 evaluation of TFA as an additive will be described in a subsequent article where mobile phases are
417 characterised.

418

419 **3.5 Peak Capacity**

420 Large selectivity differences on their own are not sufficient for generating a good chromatographic
421 method. Chromatographic efficiency is also required, which is measured by peak capacity in gradient

422 elution. Peak capacity is defined as the total number of peaks which can be resolved ($R_s = 1$) within a
423 chromatogram, and is conventionally measured by dividing the gradient time by the average peak
424 width. However, this measurement often over estimates the performance of the column, thus the
425 sample peak capacity (PC^{**}) approach was used (Eq. 5) to determine the peak capacity for the
426 fraction of the gradient used to separate all the compounds of interest [23].

$$427 \quad PC^{**} = \frac{t_{g\ max} - t_{g\ min}}{W_{ave}} + 1 \quad (5)$$

428 Where $t_{g\ min}$ and $t_{g\ max}$ are the retention time of the first and last eluting peptide. W_{ave} is the average
429 width at base for all peaks that are separated except the diastereoisomeric oxidised methionine
430 probe which is typically unresolved on most of the stationary phases.

431 The PC^{**} was measured for both the formic acid, ammonium formate and TFA gradient conditions on
432 the reduced number of delta values. The greater performance, as shown by increased PC^{**} values,
433 was typically achieved using intermediate pH (Table 6 and Fig. 6). Formic acid characteristically
434 provides poorer performance, whilst TFA usually produced good values of peak capacity. Despite
435 poorer performance, the formic acid was still within 28% on average of the peak performance
436 produced in TFA and 41% in ammonium formate.

437 Poor peak shape at low pH is often attributed to silanophilic interactions, however, with the increase
438 in modern silicas which do not possess a significant degree of acidic silanols, this cannot be the cause
439 of exaggerated peak shapes for basic species. McCalley *et al.* hypothesised that poor peak shape can
440 often be ascribed to overloading for basic species due to mutual repulsion effects between adsorbed
441 ions of the same charge [28,38-39]. This effect was increased further when low ionic strength mobile
442 phases are used. Further research by McCalley, which used positively charged peptide probes also
443 supported this theory where he compared the responses of four multiply positively charged peptides
444 in phosphate buffer, formic acid and TFA. The phosphate buffer gave significantly better peak shape
445 and chromatographic performance compared to the formic acid due to a significantly higher ion
446 strength which reduces mutual repulsion. TFA also gave improved peak shape compared to formic
447 acid, however, in this case it was also accredited to the ion pairing effects of TFA which could reduce
448 overloading by partially neutralising the net charge of the peptides and thereby removing the
449 repulsion effects [28].

450 Although formic acid can result in poor peak shape, this was not the case for the Acquity CSH range
451 of stationary phases which were specifically designed to provide an improved peak shape for basic
452 species due to the presence of a small permanent positive character on the surface of the phase

453 [40]. The Polaris Amide C18, which also possessed a positive character, additionally provided good
454 chromatographic performance in formic acid.

455

456 **3.6 Assessment of Peptide – Column Interactions**

457 **3.6.1 Hydrophobic interactions**

458 Hydrophobic interaction, which is the primary retention mechanism in reversed phase
459 chromatography, could be evaluated by investigating the effect of probes possessing differing
460 hydrophobicity (i.e. changing leucine to valine) and by changing the hydrophobicity of the stationary
461 phase (i.e. different alkyl length).

462 Mant *et al.* deduced the order of hydrophobicity for amino acids when there are no “nearest
463 neighbour” effects [27]. A purely hydrophobic interaction without “nearest neighbour” effects would
464 therefore suggest that the elution order in this study should be Val<Tyr<Ile<Leu<Phe<Trp, i.e.
465 Peptide 20<24<21<13<22<23. This was, however, not the case as seen in Fig. 7. One explanation can
466 be that the peptides in the current study lack a secondary structure in the mobile phase as shown by
467 CD but form a secondary structure in the hydrophobic acetonitrile layer on the stationary phase
468 resulting in another elution order.

469 [Leu26]- and [Val26]-Bovine GLP-2 (16-33) (Peptides 13 and 20) differ by just one methyl group,
470 which represents a subtle change in the peptide’s overall hydrophobicity, however, when compared
471 on a range of C18 phases (Acquity BEHs, HSSs and CSHs) there were substantial selectivity
472 differences between the two probes (Fig. 7 (A), (D) and (G)). This is in agreement with Mant *et al.*
473 who witnessed greater retention for a peptide modified with a leucine compared to one modified
474 with a valine [27]. [Ile26,Ile27]- and [Leu26,Ile27]-Bovine GLP-2 (16-33) (Peptides 21 and 13,
475 respectively) only differ by the position of a methylene group on the side chain, however, they have
476 substantial selectivity differences on the C18 phases during gradient elution. Literature suggests it is
477 reasonable to expect retention differences between these two peptides, as the β -branched chain on
478 the isoleucine is closer to the peptide backbone, thus less able to interact with the stationary phase
479 [27]. This is again in agreement with the previous study, where the peptide modified with leucine
480 had greater retention than the peptide modified with isoleucine.

481 [Ile26,Leu27]- possesses the same overall hydrophobicity as [Leu26,Ile27]-Bovine GLP-2 (16-33)
482 (Peptides 15 and 13, respectively), but have substantial selectivity differences on the C18 phases
483 during gradient elution (Fig. 7 and 8), which suggests an alternative mechanism. One possible
484 explanation could be that the change in position of the methyl group changes the shape of the

485 peptide in the hydrophobic acetonitrile layer on the stationary phase and that results in differences
486 in the interactions which can take place [41-43].

487 The more hydrophobic molecules [Phe26]-, [Trp26]- and [Tyr26]- (Peptides 22, 23 and 24) were then
488 compared against [Leu26]-Bovine GLP-2 (16-33) (Peptide 13). Based on retention data obtained by
489 Mant *et al.*, although they possess bulkier, aromatic side chains, a hydrophobic retention mechanism
490 should preferentially retain [Phe26]- and [Trp26]- over [Leu26]-Bovine GLP-2 (16-33) (Fig. 7). [Tyr26]-
491 Bovine GLP-2 (16-33) should be the least retained of the four peptides described. However, on all of
492 the C18 phases, [Phe26]-, [Trp26]- and [Tyr26]- eluted earlier, which confirms that a hydrophobic
493 retention mechanism must be acting in combination with an alternative mechanism.

494 The same phenomenon was experienced on the Acquity BEH alkyl range of stationary phases, where
495 a lack of pure hydrophobic mechanism was observed (Fig. 7 (A), (B) and (C)). There was a subtle
496 change in elution order for the Acquity BEH C8 and C4, however, where [Ile26]- and [Phe26]-
497 (Peptides 21 and 22) switched in elution order. One possible explanation could be that the aromatic
498 groups change the shape of the peptide in the adsorbed acetonitrile layer and thereby expose other
499 groups which can participate in polar / electrostatic interactions [41-43].

500 There are subtle selectivity differences between the stationary phases, however, to a large extent,
501 the type and length of the ligand (C4-C18) does not appear to be critical for the separation of these
502 probes.

503

504 **3.6.2 Electrostatic Interactions**

505 The addition of negative charge was evaluated using peptides [L-Asp11]- and [Asn11]-Bovine GLP-2
506 (1-15) (Peptides 9 and 1 respectively). Their retentions were compared on stationary phases with
507 negative and positive character (Fig. 9) where in formic acid, both sets of columns eluted the
508 asparagine peptide before the aspartic acid variant. In ammonium formate, however, the elution
509 order was reversed, and the aspartic acid eluted first. Under intermediate pH conditions (pH 6.45)
510 the aspartic acid peptide has a net charge of -4.7 whilst the asparagine peptide has a net charge of -
511 3.7, and as such, [L-Asp11]- would be expected to elute last on the phases with positive character
512 due to enhanced electrostatic interactions. However, as the more acidic species [L-Asp11]- eluted
513 first it suggests that despite having a greater negative charge than [Asn11]-, it is the position of the
514 charge and accessibility in the adsorbed peptides secondary structure that is important rather than
515 the overall net charge of the peptide hence the more charged / hydrophilic [L-Asp11]- elutes first.

516 The addition of positive charge was then investigated using the probes [Lys26]- and [Leu26]-Bovine
517 GLP-2 (16-33) (Peptides 26 and 13, respectively). [Lys26]- eluted first on all stationary phases and
518 mobile phases, however, there was increased retention under ammonium formate conditions due to
519 increased electrostatic interactions. The difference is most pronounced for the Acclaim Mixed Mode
520 WCX which contains a carboxylic acid functionality. At pH 6.45, the carboxylic acid is deprotonated
521 and thus the positively charged [Lys26]- becomes strongly retained. Due to repulsion, columns with
522 a positive character (the CSH series and the Polaris Amide C18 columns) elute [Lys26]- earlier at low
523 pH than columns with a negative character (i.e. more accessible silanol groups).

524 These interactions are confirmed by the position of the stationary phases and the delta values within
525 the biplot (Fig. 4).

526

527 **3.6.3 Hydrogen Bonding Interactions**

528 Prior knowledge of the stationary phases suggested those phases which are likely to form hydrogen
529 bonding interactions are the Polaris Amide C18 via the amide functionality, the Acquity BEH Shield
530 RP-18 via the embedded carbamate moiety, the Acquity BEH C4 and Acquity HSS C18-SB phases via
531 the short alkyl ligand and low ligand surface coverage respectively which both promote greater
532 accessibility to the non end-capped silanol groups on the silica surface and the Acclaim Mixed Mode
533 WCX via the carboxylic acid moiety. The Acquity BEH C18 was used as a reference since it is based
534 on hybrid silica, is end-capped and thus should have minimal potential to form hydrogen bonds. The
535 peptides [Phe26]- and [Tyr26]-Bovine GLP-2 (16-33) (Peptides 22 and 24) were assessed for
536 hydrogen bonding interactions with the stationary phases as they only differ due to the presence of
537 the hydroxyl group on the tyrosine. The phenylalanine derivative eluted last on all of the stationary
538 phases and mobile phases although with greater retentivity in ammonium formate for the tyrosine
539 variant (data not shown). The trend seems to suggest that polarity is more dominant than hydrogen
540 bonding capabilities. The extra retentivity in ammonium formate of the tyrosine peptide could
541 indicate that the stationary phase is becoming more polar. The lack of hydrogen bonding could be
542 due to the position of the amino acid change in the peptide residue. It is possible hydrogen bond
543 interactions could be more pronounced if tyrosine was located closer to the terminal amino acids.

544 There are large selectivity differences observed between the two peptides considering only a 16 Da
545 difference in their ~2300 Da structures, which indicates the addition of the hydroxyl group has
546 caused some significant changes in the interactions within the chromatographic system.

547 The position of the Acquity BEH Shield RP-18 at the origin in the score plot is highly suggestive that
548 the carbamate group masks any underlying silanol groups and the carbamate is not involved in any
549 pronounced hydrogen bonding interactions with [Tyr26]-Bovine-GLP-2 (16-33).

550

551 **3.6.4 Aromatic Interactions**

552 Phenyl containing phases (Acquity CSH Phenyl Hexyl, Fortis Diphenyl and Ascentis Biphenyl) and the
553 pentafluorophenyl phase (Acquity CSH Fluoro Phenyl) were compared against the Acquity BEH C18
554 and CSH C18 to assess for potential aromatic interactions. The probes used were [Leu26]-, [Phe26]-,
555 [Trp26]- and [Tyr26]-Bovine GLP-2 (16-33) (Peptides 13, 22, 23 and 24, respectively).

556 The CSH phases all possessed the same elution order in both formic acid and ammonium formate,
557 highlighting minimal aromatic retention which suggests the stationary phase ligand becomes less
558 important for these separations (Fig. 10).

559 The diphenyl and biphenyl phases on the other hand were able to resolve the aromatic species and
560 also had different elution orders compared to the CSH phases. [Phe26]- elutes after [Leu26]- and
561 there is a significantly larger retention of [Phe26]- at mid pH suggesting that this is due to
562 electrostatic interaction and not due to π - π interactions. The diphenyl and biphenyl phases suggest a
563 more negative character due to accessible silanol groups whereas the CSH phases have a more
564 positive character due to positively charged groups in the stationary phase, as indicated within the
565 PCA (Fig. 4 biplot).

566 There is the potential that the acetonitrile within the mobile phase could reduce any subtle aromatic
567 interactions of the peptides with the stationary phase due to competing π - π interactions. The
568 elution order based on hydrophobicity alone using Hodges's work would suggest [Tyr26]- elute first,
569 then [Leu26]-, [Phe26]- and then finally [Trp26]-Bovine GLP-2 (16-33) [27]. However, this was not the
570 case here where [Trp26]- typically eluted before [Phe26] and [Leu26]-Bovine GLP-2 (16-33). This is
571 highly suggestive that an alternative retention mechanism must be introduced, such as the
572 formation of a second order structure of the peptide in the stationary phase exposing certain
573 functional groups and hiding others.

574

575 **3.6.5 Interactions Related to Degradation of Peptides**

576 Purity methods developed for biopharmaceutical peptides should be able to separate degradation
577 products. Consequently, an important aspect of the protocol was to evaluate selectivity for common
578 degradants and racemisation products. Racemisation and isomeric products are typically

579 challenging to separate since these peptides are diastereoisomers with very similar physiochemical
580 properties. An investigation of the retention order of D- and L-forms of racemates indicate that the
581 retention order is often the same at both low and mid pH. This was the case for 78% of the 117
582 combinations of delta values and columns in the current study. A comparison of which pH typically
583 generates a higher delta value for racemates did not show any trend. In 54% of the cases mid pH
584 gave a larger delta value. A similar result was obtained for Asp / isoAsp isomeric delta values, where
585 73% of the 26 combinations often gave the same elution order in both low and mid pH. However,
586 there was a trend where low pH gave the large delta value (85% of the combinations).

587 The biplot (Fig. 4) was used to identify phases which were deemed chromatographically similar and
588 dissimilar in order to assess their ability to separate racemates. The Acquity CSH Phenyl Hexyl and
589 Acquity HSS C18-SB were selected as phases with large differences in selectivity for the separation of
590 [D-Ser16]- and [L-Ser16]-Bovine GLP-2 (16-33) (Peptide Numbers 14 and 13, respectively), whilst the
591 Acquity HSS T3 and Acquity BEH C18 were compared as phases which provide similar selectivity, i.e.
592 these phases are located at the extremes and close to the origin when projected on to a line through
593 the origin and $\Delta(14,13)$ in the bi-plot (Fig. 4).

594 The diverse columns with formic acid (Fig. 11 (A) and (B)) exhibit a difference in the degree of
595 resolution, where there is coelution but a switch in elution order on the Acquity HSS C18-SB and
596 resolution achieved on the Acquity CSH Phenyl Hexyl. By switching to ammonium formate (Fig. 11 (E)
597 and (F)), baseline resolution was achievable on the Acquity CSH Phenyl Hexyl, whilst the Acquity HSS
598 C18-SB has switched elution order. For difficult separations such as resolving racemic species, it is
599 essential to have large peak capacity which is typical for mobile phases such as ammonium formate,
600 whereas solvents which have low ionic strength, such as formic acid, typically failed to resolve the
601 two species due to poor peak shape. For an explanation of the poor peak shape, see Section 3.5.

602 In Fig. 11 (C), (D), (G) and (H), the Acquity HSS T3 and Acquity BEH C18 all produced similar looking
603 chromatograms irrespective of stationary or mobile phase, with similar selectivity and normalised
604 retention times.

605 This comparison has provided an early indication that this protocol could show differentiation
606 between the phases, even for challenging separations such as resolving racemic species. The
607 example above was selected using $\Delta(14,13)$. In order to select columns from the biplot (Fig. 4) likely
608 to give large differences in selectivity for any racemates the selection would have been Acquity BEH
609 C8, Acquity HSS C18-SB, Acquity CSH Fluoro Phenyl, Acquity CSH Phenyl Hexyl and Polaris Amide C18

610 [Met(O)₁₀]- and [Met₁₀]-Bovine GLP-2 (1-15) (Peptide Numbers 8 and 1, respectively) were
611 compared to investigate the effect of oxidation. The more hydrophilic, oxidised methionine eluted
612 first on all the stationary phases irrespective of the mobile phase conditions, with ample degree of
613 separation achieved between the two species in either formic acid or ammonium formate gradient
614 conditions.

615

616 **4 Conclusion**

617 A protocol for the characterisation of stationary phases using peptides as probes was successfully
618 developed. The protocol utilised two gradient mobile phase systems at low and intermediate pH to
619 cover different degrees of ionisation of both peptides and stationary phases.

620 The peptides were rationally designed in order to systematically change characteristics deemed
621 important for retentivity and selectivity, including hydrophobicity, aromaticity, degree of hydrogen
622 bonding, electrostatic interactions, steric interactions and important degradation pathways. The
623 peptides mixtures were injected onto 14 different stationary phases possessing different
624 chromatographic characteristics, which were grouped into neutral phases (i.e. phases with high
625 ligand density and a large degree of end-capping), negative character phases (i.e. phases with a
626 reduced ligand coverage or no end-capping present) and finally positive character phases (i.e. phases
627 with a positively charged functional group in addition to the RP ligand). Peptides were identified
628 using SIM, or where differentiation by mass was not possible (i.e. isomers) different peak area ratios
629 were used.

630 A range of delta values were calculated which covered the interactions of interest to assess
631 selectivity differences. The data was analysed using PCA, which highlighted groupings of stationary
632 phases resembling the three groups described. The number of delta values and peptides were
633 systematically reduced whilst ensuring that the integrity of the score plot was maintained.

634 Further evaluation of the data indicated that the most crucial interactions between stationary
635 phases and peptides are hydrophobic in nature, in combination with polar interactions. These
636 results, which are based on biologically relevant peptides, suggest that it is polar interactions and
637 the second order structure of the adsorbed peptide in the stationary phase that to a large extent
638 contribute to the selectivity and the differences seen between columns. This was highlighted by the
639 large selectivity differences exhibited for peptides with a similar degree of hydrophobicity. Another
640 interesting observation was the large selectivity differences exhibited for racemisation species,
641 which only differ by the orientation of one of the amino acids.

642 This first evaluation of the selectivity of peptides will be further investigated and expanded in a
643 series of articles. The robustness of the protocol will be assessed using systematic changes to the
644 methodology and practical constraints introduced to ensure the integrity of the methodology. The
645 protocol will also be applied to a greater array of stationary phases from different column
646 manufacturers to build a database for rational stationary phase selection for peptide separations
647 which will be validated with the analysis of tryptic digests of biologically active proteins. In addition,
648 the results from the database will be compared against small molecule column characterisation data
649 to ascertain any correlation between the peptide probes and conventional small molecule protocols.
650 The intention is also to utilise these peptides for the characterisation of a range of mobile phases
651 employing different pH, ion-pairing additives, organic modifiers and salts.

652

653 **5 Acknowledgements**

654 The authors are grateful to the following: Novo Nordisk for funding Jennifer Field's PhD; Marie
655 Østergaard Pedersen, Natasja Weismann Andersen and Lene Villadsen of Novo Nordisk for their
656 assistance with circular dichroism experimentation to investigate the possibility of higher order
657 peptide structure and general logistics / troubleshooting; Umetrics for providing the SIMCA PCA
658 software; Shimadzu for the supply of the LC-MS system; Agilent, Fortis, Supelco and Waters for
659 providing the columns used in this work.

660

661

662 **6 References**

- 663 [1] 20 Best Selling Drugs 2018 <https://www.igeahub.com/2018/04/07/20-best-selling-drugs-2018/>
664 [Accessed: 25/10/2018]
- 665 [2] Top 20 Drugs in the World 2017 <https://www.igea hub.com/2017/08/08/top-20-drugs-in-the->
666 [world-2017/](https://www.igea hub.com/2017/08/08/top-20-drugs-in-the-world-2017/) [Accessed: 25/10/2018]
- 667 [3] L. Moruz and L. Käll, Peptide retention time prediction, *Mass Spectrometry Review*, **36** (2017)
668 615-623
- 669 [4] T. Baczek, P. Wiczling, M. Marszałł, Y. V. Heyden, and R. Kaliszan, Prediction of peptide retention
670 at different HPLC conditions from multiple linear regression models, *J. Proteome Res.*, **4** (2005) 555-
671 563
- 672 [5] O. Krokhin, Peptide retention prediction in reversed-phase chromatography: proteomic
673 applications, *Expert Rev. Proteomics*, **9** (2012) 1-4
- 674 [6] V. Spicer, A. Yamchuk, J. Cortens, S. Sousa, W. Ens, K.G. Standing, J.A. Wilkins and O.V. Krokhin,
675 Sequence-specific retention calculator. A family of peptide retention time prediction algorithms in
676 reversed-phase HPLC: Applicability to various chromatographic conditions and columns, *Anal. Chem.*,
677 **79** (2007) 8762-8768
- 678 [7] N. Pfeifer, A. Leinenback, C.G. Huber and O. Kohlbacher, Statistical learning of peptide retention
679 behaviour in chromatographic separations: a new kernel-based approach for computational
680 proteomics, *BMC Bioinformatics* **8** (2007) 468-482
- 681 [8] M.R. Euerby, M. Fever, J. Hulse, M. James, P. Petersson and C. Pipe, Maximization of selectivity in
682 reversed-phase liquid chromatographic method development strategies, *LCGC Europe* **29** (2016) 8-
683 21
- 684 [9] M.R. Euerby and P. Petersson, Chromatographic classification and comparison of commercially
685 available reversed-phase liquid chromatographic columns using principal component analysis *J.*
686 *Chromatogr. A* **994** (2003) 13-36
- 687 [10] K. Kimata, K. Iwaguchi, S. Onishi, K. Jinno, R. Eksteen, K. Hosoya, M. Araki and N. Tanaka,
688 Chromatographic characterization of silica C18 packing materials- Correlation between a preparation
689 method and retention behaviour of stationary phase, *J. Chromatogr. Sci.* **27** (1989) 721-728
- 690 [11] ACD Column Selection Database <https://www.acdlabs.com/resources/freeware/colsel/>
691 [Accessed: 25/10/2018]

- 692 [12] L.R. Snyder, J.W. Dolan and P.W. Carr, The hydrophobic subtraction model of reversed-phase
693 column selectivity, *J. Chromatogr. A* **1060** (2004) 77-116
- 694 [13] U.S. Pharmacopeial Convention <http://apps.usp.org/app/USPNF/columnsIntro.html> [Accessed:
695 25/10/2018]
- 696 [14] C. West, E. Lemasson, S. Bertin, P. Hennig and E. Lesellier, An improved classification of
697 stationary phases for ultra-high performance supercritical fluid chromatography, *J. Chromatogr. A*
698 **1440** (2016) 212-228
- 699 [15] C.T. Mant and R.S. Hodges, Design of peptide standards with the same composition and minimal
700 sequence variation to monitor performance/selectivity of reversed-phase matrices, *J. Chromatogr. A*
701 **1230** (2012) 30-40
- 702 [16] C.T. Mant, D. Cepeniene and R.S. Hodges, Reversed-phase HPLC of peptides: Assessing column
703 and solvent selectivity on standard, polar-embedded and polar endcapped columns, *J. Sep. Sci.* **33**
704 (2010) 3005-3021
- 705 [17] P. Petersson, B.O. Boateng, J.K. Field and M.R. Euerby, A practical approach to modelling of
706 reversed-phase liquid chromatographic separations: Advantages, principles and possible pitfalls,
707 *LCGC Europe* **31** (2018) 120-143
- 708 [18] M.R. Euerby and P. Petersson, Chromatographic classification and comparison of commercially
709 available reversed-phase liquid chromatographic columns containing polar embedded groups/amino
710 endcappings using principal component analysis, *J. Chromatogr. A* **1088** (2005) 1-15
- 711 [19] P. Petersson and M.R. Euerby, An evaluation of the robustness of the Tanaka characterisation
712 protocol for reversed-phase liquid chromatography columns, *J. Sep. Sci.*, **28** (2005) 2120-2129
- 713 [20] S. Ventura and R.J.Y. Chang, Oxidative folding: coupling conformation folding and disulphide
714 formation, in: M.Z. Atassi (Eds.), *Folding of Disulfide Proteins*, Springer, New York, 2011 pp. 1-22
- 715 [21] R.I. Boysen and M.T.W. Hearn, Chapter 5: High performance liquid chromatography of peptides
716 and proteins, in: A.B. Hughes (Eds.), *Amino Acids, Peptides and Proteins in Organic Chemistry:
717 Analysis and Function of Amino Acids and Peptides*. Wiley, Chichester, 2011, pp. 167-210
- 718 [22] N.J. Greenfield, Using circular dichroism spectra to estimate protein secondary structure, *Nature*
719 *Protocols*, **1** (2006) 2876-2890
- 720 [23] G.G. Smith and G.V. Reddy, Effect of the side chain on the racemization of amino acids in
721 aqueous solution, *J. Org. Chem* **54** (1989) 4529-4535

- 722 [24] Y. Yang, Peptide racemisation, in: Side reactions in Peptide Synthesis, first ed., Academic Press,
723 Cambridge, MA, 2015, pp. 257-292
- 724 [25] O. Takahashi, Racemization of the succinimide intermediate formed in proteins and peptides: A
725 computational study of the mechanism catalysed by dihydrogen phosphate ion, *Inter. J. Mol. Sci.*, **17**
726 (2016) 1698-1707
- 727 [26] T. Geiger and S. Clarke, Deamidation, isomerization and racemization at asparaginy and aspartyl
728 residues in peptides, *J. Bio. Chem.*, **262** (1987) 785
- 729 [27] J.M. Kovacs, C.T. Mant and R.S. Hodges, Determination of intrinsic hydrophilicity /
730 hydrophobicity of amino acid side chains in peptides in the absence of nearest-neighbour or
731 conformation effects, *Biopolymers (Peptide Science)* **84** (2006) 283-297
- 732 [28] D.V. McCalley, Study of overloading of basic drugs and peptides in reversed-phase high
733 performance liquid chromatography using pH adjustment of weak acid mobile phases suitable for
734 mass spectrometry, *J. Chromatogr. A.*, **1075** (2005) 57-64
- 735 [29] D.V. McCalley, Choice of buffer for the analysis of basic peptides in reversed-phase HPLC, *LCGC*
736 *Asia Pacific*, **8** (2005) 40-47
- 737 [30] J.W. Dolan, Ion pairing – Blessing or curse? *LCGC North America* **26** (2008) 170-174
- 738 [31] L. Greenspan, Humidity fixed points of binary saturated aqueous solutions, *J. Res. 'N.B.S. -Phys.*
739 *& Chem.* **81** (1977) 89-96
- 740 [32] P. Jandera, Can the theory of gradient liquid chromatography be useful in solving practical
741 problems? *J. Chromatogr. A.*, **1126** (2006) 195-218
- 742 [33] L.R. Snyder and J.W. Dolan, High performance gradient elution, John Wiley & sons, Hoboken, NJ,
743 2007
- 744 [34] P. Jandera and J. Churácék, Gradient elution in column liquid chromatography, 1st Ed. Theory
745 and Practice. Elsevier, Amsterdam, Netherlands, 1985
- 746 [35] N. Lundell, Implementation and use of gradient predictions for optimization of reversed-phase
747 liquid chromatography of peptides, *J. Chromatogr. A* **639** (1993) 97-115
- 748 [36] I.T. Jolliffe, Principal Component Analysis, Springer, Berlin 2011

- 749 [37] J.K. Field, M.R. Euerby and P. Petersson, Investigation into reversed-phase chromatography
750 peptide separation systems Part II: An evaluation of the robustness of a protocol for column
751 characterisation, *J. Chromatogr. A* (Submitted for publication Nov 2018)
- 752 [38] D.V. McCalley, Overload for ionised solutes in reversed-phase high performance liquid
753 chromatography, *Anal. Chem.*, **76** (2006) 2532-2538
- 754 [39] S.M.C. Buckenmaier, D.V. McCalley, and M.R. Euerby, Overloading study of bases using
755 polymeric RP-HPLC columns as an aid to rationalisation of overloading on silica-ODS phases, *Anal.*
756 *Chem.*, **74** (2002) 4672-4681
- 757 [40] P.C. Iraneta, K.D. Wyndham, D.R. McCabe and T.H. Walter, *A review of Waters hybrid particle*
758 *technology. Part 3. Charged Surface Hybrid (CSH) technology and its uses in liquid chromatography,*
759 (2011) <http://www.waters.com/webassets/cms/library/docs/720003929en.pdf> [Accessed:
760 25/10/2018]
- 761 [41] S. Bocian, A. Felinger and B. Buszewski, Comparison of solvent adsorption on chemically bonded
762 stationary phases in RP-LC, *Chromatographia* **68** (2008) s19-s26
- 763 [42] S. Bocian, P. Vajda, A. Felinger and B. Buszewski, Solvent excess adsorption on the stationary
764 phases for reversed-phase liquid chromatography with polar functional groups, *J. Chromatogr. A.*
765 **1204** (2008) 35-41
- 766 [43] S.M. Melnikov, A. Hölzel, A. Seidel-Morgenstern and L. Tallarek, Adsorption of water-
767 acetonitrile mixtures to model silica surfaces, *J. Phys. Chem. C.*, **117** (2013) 6620-6631

768 **7 Figure captions**

769 Fig. 1. Example test mixture containing the two reference peptides used to normalise retention.

770 Fig. 2. Loading plot of all 66 delta values showing to what extent different delta values contribute to
771 the two principal components.

772 Fig. 3. Score plot showing how columns are grouped based on the 66 delta values

773 Fig. 4. Biplot of the Peptide RPC Column Characterisation Protocol delta values on the 13 stationary
774 phases. The different stationary phase have been grouped and colour coded based on prior
775 knowledge of stationary phase properties.

776 Fig. 5. Biplots of the reduced number of delta values on the 13 stationary phases in (A) formic acid
777 and (B) TFA. The different stationary phase have been grouped and colour coded based on prior
778 knowledge of stationary phase properties.

779 Fig. 6. Sample peak capacity for each column in the score plot measured in formic acid (solid line),
780 ammonium formate (dotted line) and TFA (dashed line). A large circle indicates a high peak capacity.

781 Fig. 7. Comparison of (A) Acquity BEH C18 (B) Acquity BEH C8 (C) Acquity BEH C4 (D) Acquity HSS C18
782 (E) Acquity HSS C18-SB (F) Acquity HSS T3 (G) Acquity CSH C18 (H) Acquity CSH Phenyl Hexyl (I)
783 Acquity CSH Fluoro Phenyl to investigate hydrophobic interactions (Peptide 13: [Leu26,Ile27]-, 15:
784 [Ile26,Leu27]-, 20: [Val26,Ile27]-, 21: [Ile26,Ile27]-, 22: [Phe26,Ile27]-, 23: [Trp26,Ile27]-Bovine GLP-2
785 (16-33)). Data with bars above the retention axis correspond to low pH whereas below the axis
786 correspond to intermediate pH.

787 Fig. 8. [Leu26,Ile27]- and [Ile26,Leu27]-Bovine GLP-2 (Peptides 13 and 15) on the Acquity BEH C8
788 chromatographed using the ammonium formate gradient.

789 Fig. 9. Comparison of (A) Acquity BEH C18, (B) Acquity CSH C18 (C) Acquity CSH Phenyl Hexyl (D)
790 Acquity CSH Fluoro Phenyl (E) Polaris Amide C18 (F) Fortis Diphenyl (G) Ascentis Express Biphenyl (H)
791 Acclaim Mixed Mode WCX (I) Acquity BEH C4 (J) Acquity HSS C18-SB to investigate electrostatic
792 interactions (Peptide 1: [Asn11]-, 9: [L-Asp11]-Bovine GLP-2 (1-15), 13: [Leu26]-, 26: [Lys26]-Bovine
793 GLP-2 (16-33)). Data with bars above the retention axis correspond to low pH whereas below the
794 axis correspond to intermediate pH.

795 Fig. 10. Comparison of (A) Acquity BEH C18 (B) Fortis Diphenyl (C) Ascentis Express Biphenyl (D)
796 Acquity CSH Fluoro Phenyl (E) Acquity CSH C18 (F) Acquity CSH Phenyl Hexyl to investigate aromatic
797 interactions (Peptide 13: [Leu26]-, 22: [Phe26]-, 23: [Trp26]-, 24: [Tyr26]-Bovine GLP-2 (16-33)). Data
798 with bars above the retention axis correspond to low pH whereas below the axis correspond to
799 intermediate pH.

800 Fig. 11. Chromatograms of (13) [L-Ser16]- and (14) [D-Ser16]-Bovine GLP-2 (16-33) on phases
801 predicted to be similar or dissimilar based on the biplot in Fig. 4. From L-R: Acquity HSS C18-SB,
802 Acquity CSH Phenyl Hexyl, Acquity HSS T3, Acquity BEH C18, A-D in formic acid, E-H in ammonium
803 formate.

Table 1

Stationary phase used in the development of the Peptide RPC Column Characterisation Protocol and their physical parameters

| Manufacturer | Column | Pore Size (Å) | Particle Size (µm) | Description |
|--------------|---------------------------|---------------|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Waters | Acquity UPLC BEH C4 | 300 | 1.7 | A non endcapped, trifunctional C4 alkyl ligand bonded to ethyl bridged silica hybrid material |
| Waters | Acquity BEH C8 | 130 | 1.7 | An endcapped, trifunctional C8 alkyl ligand bonded to ethyl bridged silica hybrid material |
| Waters | Acquity UPLC BEH C18 | 130 | 1.7 | An endcapped, trifunctional C18 alkyl ligand bonded to ethyl bridged silica hybrid material |
| Waters | Acquity BEH Shield RP18 | 130 | 1.7 | An endcapped, monofunctional alkyl ligand with an embedded carbamide functionality bonded to ethyl bridged silica hybrid material |
| Waters | Acquity CSH C18 | 130 | 1.7 | An endcapped, trifunctional C18 alkyl ligand bonded to ethyl bridged silica hybrid material which possesses a low level positive surface charge |
| Waters | Acquity CSH Fluoro Phenyl | 130 | 1.7 | A non endcapped, trifunctional pentafluorophenyl moiety ligand bonded to ethyl bridged silica hybrid material which possesses a low level positive surface charge |
| Waters | Acquity CSH Phenyl Hexyl | 130 | 1.7 | An endcapped, trifunctional C6 alkyl chain with a terminal phenyl functionality bonded to ethyl bridged silica hybrid material which possesses a low level positive surface charge |
| Waters | Acquity HSS C18 | 100 | 1.8 | An endcapped, trifunctional C18 alkyl ligand |
| Waters | Acquity HSS C18 SB | 100 | 1.8 | A non endcapped, trifunctional C18 alkyl phase with low ligand density |
| Waters | Acquity HSS T3 | 100 | 1.8 | An endcapped, trifunctional, 100% aqueous compatible C18 alkyl phase with reduce ligand density |
| Agilent | Polaris Amide C18 | 180 | 3 | An endcapped, monofunctional alkyl ligand with an embedded amide functionality which possesses positive character due to residual amino groups related to a two step synthetic process |
| Supelco | Ascentis Express Biphenyl | 90 | 2.7 | An endcapped, superficially porous particle with a biphenyl ligand |
| Fortis | Fortis Diphenyl | 100 | 1.7 | An endcapped, diphenyl ligand |
| Thermo | Acclaim Mixed Mode WCX | 120 | 3 | A mixed mode ligand composed of an alkyl chain with carboxylic acid terminus |

Table 2

Peptide sequence of Bovine GLP-2

| Amino Acid # | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 |
|--------------|---|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|
| Bovine GLP-2 | H | A | D | G | S | F | S | D | E | M | N | T | V | L | D | S | L | A | T | R | D | F | I | N | W | L | I | Q | T | K | I | T | D |

Table 4

List of delta values, their rationale and the average Δt_g and Δt_g^* in formic acid, TFA or ammonium formate

| Delta | Change | Rationale | Average Δt_g in FA (min) | Average Δt_g^* in FA (-) | Average Δt_g in TFA (min) | Average Δt_g^* in TFA (-) | Average Δt_g in AF (min) | Average Δt_g^* in AF (-) |
|-------------------|-----------------------------------------|---------------------------------------------|-------------------------------------|-------------------------------------|--------------------------------------|--------------------------------------|-------------------------------------|-------------------------------------|
| $\Delta(2,1)$ | [L-His1] → [D-His1] | Steric - racemisation | 0.091 | 0.009 | | | 0.315 | 0.016 |
| $\Delta(3,1)$ | [L-Asp3] → [D-Asp3] | Steric - racemisation | -0.026 | 0.004 | | | -0.076 | -0.001 |
| $\Delta(4,1)$ | [L-Asp3] → [L-isoAsp3] | Increase in negative charge | 0.078 | 0.016 | | | -0.263 | -0.008 |
| $\Delta(5,1)$ | [L-Asp3] → [D-isoAsp3] | Increase in negative charge | 0.395 | 0.038 | | | 0.049 | 0.006 |
| $\Delta(5,4)$ | [L-isoAsp3] → [D-isoAsp3] | Steric - racemisation | 0.317 | 0.022 | | | 0.311 | 0.014 |
| $\Delta(6,1)$ | [L-Ser5] → [D-Ser5] | Steric - racemisation | 0.006 | 0.008 | | | 0.283 | 0.016 |
| $\Delta(7,1)$ | [L-Ser7] → [D-Ser7] | Steric - racemisation | -0.619 | -0.036 | | | -0.051 | 0.002 |
| $\Delta(8a,1)^*$ | [Met10] → [Met(O)10] | Oxidation | -4.166 | -0.289 | -3.655 | -0.278 | -3.598 | -0.157 |
| $\Delta(8b,1)^*$ | [Met10] → [Met(O)10] | Oxidation | -4.085 | -0.283 | | | -3.542 | -0.154 |
| $\Delta(8b,8a)^*$ | [Met(O)10] → [Met(O)10] | Steric - racemisation | 0.081 | 0.006 | | | 0.056 | 0.003 |
| $\Delta(9,1)$ | [L-Asn11] → [L-Asp11] | Increase in negative charge | 0.802 | 0.059 | 0.583 | 0.044 | -1.142 | -0.055 |
| $\Delta(10,1)$ | [L-Asn11] → [D-Asp11] | Increase in negative charge | 0.575 | 0.044 | | | -1.786 | -0.083 |
| $\Delta(10,9)$ | [L-Asp11] → [D-Asp11] | Steric - racemisation | -0.228 | -0.016 | | | -0.644 | -0.028 |
| $\Delta(11,1)$ | [L-Asn11] → [L-isoAsp11] | Increase in negative charge | -1.232 | -0.078 | | | -2.569 | -0.115 |
| $\Delta(12,1)$ | [L-Asn11] → [D-isoAsp11] | Increase in negative charge | -0.648 | -0.038 | | | -2.148 | -0.098 |
| $\Delta(12,11)$ | [L-isoAsp11] → [D-isoAsp11] | Steric - racemisation | 0.584 | 0.040 | | | 0.421 | 0.017 |
| $\Delta(14,13)$ | [L-Ser16] → [D-Ser16] | Steric - racemisation | -0.100 | 0.007 | -0.167 | -0.013 | 0.297 | 0.011 |
| $\Delta(15,13)$ | [Leu26,Ile27] → [Ile26,Leu27] | Steric – switch in amino acid sequence | 0.491 | 0.047 | 0.443 | 0.033 | 1.118 | 0.049 |
| $\Delta(16,13)$ | [L-Asp21,Phe22] → [L-Asp21,Gly22] | Aromatic – removal of aromatic group | -5.927 | -0.404 | -4.425 | -0.329 | -7.037 | -0.312 |
| $\Delta(17,16)$ | [L-Asp21,Gly22] → [D-Asp21,Gly22] | Steric - racemisation | 0.129 | -0.004 | | | 0.929 | 0.038 |
| $\Delta(18,16)$ | [L-Asp21,Gly22] → [L-isoAsp21,Gly22] | Increase in negative charge | 0.652 | 0.036 | | | 1.122 | 0.052 |
| $\Delta(19,16)$ | [L-Asp21,Gly22] → [D-isoAsp21,Gly22] | Increase in negative charge | 0.421 | 0.017 | | | 0.902 | 0.044 |
| $\Delta(19,18)$ | [L-isoAsp21,Gly22] → [D-isoAsp21,Gly22] | Steric - racemisation | -0.231 | -0.019 | | | -0.220 | -0.009 |
| $\Delta(20,13)$ | [Leu26] → [Val26] | Alkyl – removal of -CH ₂ | -2.025 | -0.117 | | | -1.745 | -0.075 |
| $\Delta(21,13)$ | [Leu26] → [Ile26] | Alkyl – change of -CH ₃ position | -0.924 | -0.033 | | | -0.456 | -0.018 |
| $\Delta(22,13)$ | [Leu26] → [Phe26] | Aromatic – addition of aromatic group | -0.803 | -0.023 | | | -0.338 | -0.014 |
| $\Delta(23,13)$ | [Leu26] → [Trp26] | Aromatic – addition of aromatic group | -1.201 | -0.056 | | | -0.962 | -0.039 |
| $\Delta(23,22)$ | [Phe26] → [Trp26] | Aromatic – addition of aromatic group | -0.398 | -0.032 | | | -0.624 | -0.025 |
| $\Delta(24,13)$ | [Leu26] → [Tyr26] | Phenolic – addition of hydroxyl group | -3.648 | -0.236 | -2.791 | -0.210 | -3.835 | -0.164 |
| $\Delta(24,22)$ | [Phe26] → [Tyr26] | Phenolic – addition of hydroxyl group | -2.844 | -0.212 | | | -3.497 | -0.151 |
| $\Delta(24,23)$ | [Trp26] → [Tyr26] | Phenolic – addition of hydroxyl group | -2.447 | -0.180 | | | -2.873 | -0.126 |
| $\Delta(25,13)$ | [Arg20] → [Lys20] | Change in polarity | -0.767 | -0.012 | | | -0.116 | -0.004 |
| $\Delta(26,13)$ | [Leu26] → [Lys26] | Increase in positive charge | -8.213 | -0.587 | -5.926 | -0.457 | -6.773 | -0.279 |

*a and b corresponds to the first and last eluting isomer of [Met(O)10]-Bovine GLP-2 (1-15)

NB The sign prior to the Δt_g^* in mins indicates the elution order e.g. [Leu26] → [Lys26] with a Δt_g of -8.213 means that [Lys26] elutes earlier than [Leu26]

Table 5

Final test mixtures used for the Peptide RPC Column Characterisation Protocol


| Test Mixture | Delta | Measured in Formic Acid | Measured in Ammonium Formate |
|--------------|------------------|-------------------------|------------------------------|
| TM1 | $\Delta(8a,1)^*$ | ✓ | |
| TM1 | $\Delta(9,1)$ | ✓ | ✓ |
| TM1 | $\Delta(15,13)$ | | ✓ |
| TM1 | $\Delta(16,13)$ | ✓ | |
| TM1 | $\Delta(24,13)$ | | ✓ |
| TM2 | $\Delta(10,9)$ | | ✓ |
| TM2 | $\Delta(26,13)$ | ✓ | ✓ |
| TM3 | $\Delta(3,1)$ | | ✓ |
| TM3 | $\Delta(14,13)$ | ✓ | |

*a corresponds to the first eluting isomer of [Met(O)10]-Bovine GLP-2 (1-15)

Table 6


Peak capacity measured for each stationary phase using both the formic acid, TFA and ammonium formate gradients


| <i>PC**</i> | Acquity BEH C4 | Acquity BEH C8 | Acquity BEH C18 | Acquity BEH Shield RP-18 | Acquity CSH C18 | Acquity CSH Fluoro Phenyl | Acquity CSH Phenyl Hexyl | Acquity HSS C18 | Acquity HSS C18-SB | Acquity HSS T3 | Ascentis Express Biphenyl | Fortis Diphenyl | Polaris Amide C18 |
|-------------------------|-------------------|-------------------|--------------------|-----------------------------|--------------------|------------------------------|-----------------------------|--------------------|-----------------------|-------------------|---------------------------------|--------------------|----------------------|
| Formic Acid | 90 | 121 | 123 | 137 | 146 | 78 | 108 | 80 | 108 | 64 | 66 | 66 | 79 |
| Trifluoroacetic Acid | 172 | 137 | 174 | 168 | 173 | 140 | 147 | 142 | 68 | 81 | 129 | 130 | 108 |
| Ammonium Formate | 129 | 212 | 222 | 229 | 196 | 124 | 180 | 173 | 81 | 183 | 193 | 122 | 96 |





Delta Value Character


- Alkyl
- ◆ Aromatic
- ◆ Negative charge
- ◆ Oxidation
- ◆ Phenolic
- Positive charge
- ★ Steric

































Formic Acid



Ammonium Formate

